GlassScriptPhysician profile
Sara E Brooks
NPI 1811154057
$6,290.48
in general payments reported to CMS, 2019-2025
41 companies · $1,014 in 2025
The $1,014 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $771 · 2020: $411 · 2021: $690 · 2022: $894 · 2023: $1,275 · 2024: $1,234 · 2025: $1,014.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,444 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,444.20 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $854.43 | 2019-2025 | |
| Janssen Biotech, INC. | $641.98 | 2020-2025 | Tremfya |
| Genzyme Corporation | $598.46 | 2019-2025 | |
| Abbvie INC. | $529.31 | 2019-2025 | Skyrizi |
| Lilly USA, LLC | $421.04 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Incyte Corporation | $312.38 | 2022-2025 | Opzelura |
| Journey Medical Corporation | $272.76 | 2022-2023 | |
| Amgen INC. | $263.49 | 2019-2025 | Otezla, Otezla |
| Pfizer INC. | $222.21 | 2019-2023 | |
| Celgene Corporation | $196.87 | 2019 | |
| Galderma Laboratories, L.P. | $189.13 | 2019-2025 | Nemluvio, Aklief |
| Revance Therapeutics, INC. | $151.98 | 2024 | Daxxify |
| Janssen Scientific Affairs, LLC | $147.75 | 2023 | Tremfya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $137.39 | 2019-2024 | Jublia, Arazlo, Cabtreo |
| E.R. Squibb & Sons, L.L.C. | $132.64 | 2020-2024 | Sotyktu |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Brooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.